Logo.png
IMUNON Releases Enterprise Video Highlighting the Company’s Mission, Vision, Values, Breakthroughs and Technologies
September 26, 2023 08:30 ET | Imunon, Inc.
Provides a look at the new manufacturing facility in Huntsville, Alabama Introduced as part of IMUNON's newly relaunched website LAWRENCEVILLE, N.J., Sept. 26, 2023 (GLOBE NEWSWIRE) --...
Logo.png
Imunon Reports Inducement Grants under NASDQ Listing Rule 5646(c)(4)
March 21, 2023 16:30 ET | Imunon, Inc.
LAWRENCEVILLE, N.J., March 21, 2023 (GLOBE NEWSWIRE) -- Imunon, Inc. (NASDAQ: IMNN), a clinical-stage drug development company focused on DNA-based immunotherapy and next-generation vaccines, today...
Logo.png
IMUNON Announces Strategic Investment in Transomic Technologies
November 17, 2022 08:30 ET | Imunon, Inc.
Investment of $375,000 with Senior Convertible Notes and Warrants; Strengthens Development Capabilities for IMUNON’s PLACCINE DNA Vaccine Platform IMUNON’s Executive Chairman to join Transomic’s...
LOGO.jpg
Celsion Corporation Reports Second Quarter 2022 Financial Results and Provides Business Update
August 15, 2022 08:00 ET | Celsion Corporation
DNA Mediated Immunotherapy and Next-Generation Vaccine Programs Supported with a Strong Balance Sheet Conference Call Begins Today at 11:00 a.m. EDT LAWRENCEVILLE, N.J., Aug. ...
LOGO.jpg
Celsion Corporation to Hold Second Quarter 2022 Financial Results and Business Update Conference Call on Monday, August 15, 2022
August 08, 2022 08:30 ET | Celsion Corporation
LAWRENCEVILLE, N.J., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage development company focused on DNA-based immunotherapy and next-generation vaccines,...
LOGO.jpg
Celsion Corporation Reports Inducement Grants under NASDQ Listing Rule 5646(c)(4)
July 19, 2022 08:35 ET | Celsion Corporation
LAWRENCEVILLE, N.J., July 19, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage company focused on DNA-based immunotherapy and next-generation vaccines, today announced...
LOGO.jpg
Celsion Corporation to Hold First Quarter 2022 Financial Results and Business Update Conference Call on Monday, May 16, 2022
May 09, 2022 08:30 ET | Celsion Corporation
LAWRENCEVILLE, N.J., May 09, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage development company focused on DNA-based immunotherapy and next-generation vaccines,...
LOGO.jpg
Celsion Corporation Reports 2021 Financial Results and Provides Business Update
March 31, 2022 08:30 ET | Celsion Corporation
Focus on Cancer Immunotherapy and Next-Generation Vaccines and a Strong Balance Sheet Conference Call Begins Today at 11:00 a.m. Eastern Time LAWRENCEVILLE, N.J., March 31, 2022 (GLOBE NEWSWIRE)...
LOGO.jpg
Celsion Corporation to Hold Year-End 2021 Financial Results and Business Update Conference Call on Thursday, March 31, 2022
March 24, 2022 09:00 ET | Celsion Corporation
LAWRENCEVILLE, N.J., March 24, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage development company focused on DNA-based immunotherapy and next-generation vaccines,...
LOGO.jpg
Celsion Receives $1.4 Million from Sale of its New Jersey State Net Operating Losses
February 28, 2022 09:00 ET | Celsion Corporation
Non-dilutive funding further strengthens balance sheet and extends current operating runway through 2024 Additional $3.5 million of unused state NOLs expected to be sold in future years ...